Dr Reddy’s Labs shares up 3% after Q2 results. What should investors do?

November 6, 2024

Dr. Reddy’s Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While analysts acknowledge the strong revenue momentum, opinions are divided on the stock’s future prospects, with ratings ranging from ‘Buy’ to ‘Sell’.

More To Explore

South Korean shares hit record as chipmakers surge on OpenAI deal

South Korean shares soared to a record high on Thursday, driven by a significant surge in chipmakers Samsung Electronics and SK Hynix. Both companies secured

October 2, 2025

Bond markets get a boost as RBI holds rates and hints at future easing

The RBI’s MPC kept policy rates unchanged at 5.5% in its October 2025 review, maintaining a neutral stance while signaling room for future easing. Experts

October 2, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003